CORE--CLINICAL

临床核心的主要目标将是在ADRC维持一个由375-400名志愿者患者和对照组成的小组，以及作为我们在丘拉维斯塔的卫星诊所的西班牙裔计划的一部分的100名志愿者患者和对照，并招募具有轻度认知障碍的新D受试者（定义为DRS>109，他们中的许多人将离开MMSE >24/30，以取代已经变得更受损的受试者。在此竞争性更新期间，我们将增加特定患者和对照组的招募，以满足研究需求。将特别强调招募80岁以上的对照，以满足对老年对照脑进行更多尸检以进行临床-病理学相关性的需求，并满足对老年对照脑进行更多尸检以进行临床-病理学相关性的需求，以及满足研究遗传标记的需求（因为Apo-E ε 4作为AD的主要易感性因素的作用在80岁后减弱）。年度参与者评价将包括人口统计学、历史、医学、神经学、精神病学和神经心理学检查，以帮助诊断并跟踪认知和神经学进展的年度变化。 这些评估提供了一个行为数据库，可用于与ADRC相关的各种研究项目，此外，还提供了有关AD病程和进展的详细纵向数据。 临床中心维护各种研究者使用的成纤维细胞培养物、DNA、血浆样本和CSF库。临床核心提供了允许参与多中心试验和协作数据和遗传分析的来源，并为圣地亚哥的其他D研究者提供了一个特征良好的队列。最后，将开展开发工作，以提高我们早期诊断AD的能力，并改善其他痴呆症的诊断，如与Lew体和额颞叶痴呆症相关的痴呆症。

The principle objective of the Clinical Core will be to maintain a panel of 375-400 volunteer patients and controls at the ADRC, and 100 volunteer patients & controls as part of our Hispanic initiative at our satellite clinic in Chula Vista, and to recruit new D subjects with a mild degree of cognitive impairment (defined as DRS>109, many of whom will leave MMSE >24/30 to replace subjects who have become more impaired. During the period of this competing renewal we will increase our recruitment of specific groups of patients and controls to meet research needs. Particular emphasis will be to recruit controls over the age of 80 in order to meet the need for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet for a greater number of autopsies of elderly control brains for clinical-pathological correlations and to meet the needs of those studying genetic markers (since the effect of Apo-Eepsilon4 as the major susceptibility factor for AD diminishes after age 80). Annual participant evaluations will include demographic, historical, medical, neurological, psychiatric and neuropsychological examinations to aid in diagnosis and to track yearly changes in cognitive and neurological progression. The evaluations provide a behavioral data base that can be used by the various research projects associated with the ADRC and in addition, provide detailed longitudinal data on the course and progression of AD. The Clinical Core maintains banks of fibroblast cultures, DNA, plasma samples, and CSF that are used by a variety of investigators. The Clinical Core provides the sources that permits participation multicenter trials and collaboration data and genetic analysis, as well as supply a well characterized cohort to other D investigators in San Diego. Finally, developmental work will be undertaken to improve our ability to diagnose AD early and to improve the diagnosis of other dementias such as dementia associated with Lew bodies and fronto-temporal dementia.